Taken together, these results suggest that CXCR3 inhibition in oropharynx squamous cell carcinoma should be used with caution, as these agents may stimulate tumor growth considering the competing effects of this cytokine axis. This evidence concerns the gene CXCR3 and oropharynx squamous cell carcinoma.